BLK
69
3
PM
66
6
NWS
62
4
COF
60
3
TGNA
37
-3
ADBE
43
3
NTRS
54
4
ETR
66
3
JPM
59
3
HRL
30
3
LUV
40
2
OMC
62
3
CL
50
2
PFE
21
-2
XYL
35
4
SYY
45
2
ADM
16
-9
DOV
61
4
PPL
54
5
KEY
34
3
BLK
69
3
PM
66
6
NWS
62
4
COF
60
3
TGNA
37
-3
ADBE
43
3
NTRS
54
4
ETR
66
3
JPM
59
3
HRL
30
3
LUV
40
2
OMC
62
3
CL
50
2
PFE
21
-2
XYL
35
4
SYY
45
2
ADM
16
-9
DOV
61
4
PPL
54
5
KEY
34
3
Financhill
Back

Emergent BioSolutions 10K Form

Sell
39

EBS
Emergent BioSolutions

Last Price:
9.19
Seasonality Move:
6.33%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-02 10Q EBS/Emergent BioSolutions Quarterly
2023-12-11 10Q EBS/Emergent BioSolutions Quarterly
2023-08-09 10Q EBS/Emergent BioSolutions Quarterly
2023-05-10 10Q EBS/Emergent BioSolutions Quarterly
2022-11-09 10Q EBS/Emergent BioSolutions Quarterly
2022-08-02 10Q EBS/Emergent BioSolutions Quarterly

Receive EBS News And Ratings

See the #1 stock for the next 7 days that we like better than EBS

EBS Financial Statistics

Sales & Book Value

Annual Sales: $1.02B
Cash Flow: $42.9M
Price / Cash Flow: 12.43
Annual Sales: $7.30
Price / Book: 1.23

Profitability

EPS (TTM): -11.24000
Net Income (TTM): $-587M
Gross Margin: $317.6M
Return on Equity: -87.53%
Return on Assets: -31.86%

Emergent BioSolutions Earnings Forecast

Key Emergent BioSolutions Financial Ratios

  • The Gross Profit Margin over the past 22 years for EBS is 31.05%.
  • The Selling, General & Administrative Expenses for EBS have been equal to 36.01% of Gross Profit Margin.
  • The Research & Development expenses have been 10.89% of Revenue.
  • The Interest Expense is -11.56% of Operating Income.
  • The Net Earning history of EBS is -74.34% of Total Revenues.
  • Per Share Earnings over the last 23 years have been positive in 12 years.

Emergent BioSolutions Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Biotechnology
Sector: Health Care
Current Symbol: EBS
CUSIP: 29089Q
Website: emergentbiosolutions.com

Debt

Debt-to-Equity Ratio: 2.23
Current Ratio: 1.06
Quick Ratio: 0.43

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 3

EBS Technical Analysis vs Fundamental Analysis

Sell
39
Emergent BioSolutions (EBS) is a Sell

Is Emergent BioSolutions a Buy or a Sell?